US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

1.89

-0.0600-3.08%

Post-market: 1.920.0300+1.59%18:23 EST

Volume:259.46K

Turnover:501.07K

Market Cap:41.63M

PE:-0.82

High:2.00

Open:2.00

Low:1.87

Close:1.95

52wk High:8.94

52wk Low:1.68

Shares:22.03M

Float Shares:15.49M

Volume Ratio:0.73

T/O Rate:1.68%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3103

EPS(LYR):-1.1597

ROE:-2660.81%

ROA:-170.69%

PB:-45.75

PE(LYR):-1.63

Loading ...

Overview Company News Filings

Medicus Pharma Raises $5.1 Million Through Warrant Exercise

Medicus Pharma Names Carolyn Bonner President and CFO

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

THOMSON REUTERS

Medicus Pharma Completes Acquisition of UK-Based Biotech Antev

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Optimistic Buy Rating for Medicus Pharma Ltd Driven by Promising SkinJect Developments and Strategic Initiatives

Medicus Pharma Is Maintained at Buy by D. Boral Capital

BRIEF-Medicus Pharma Announces Filing Of FDA Commissioner’s National Priority Voucher Application (Cnpv) For Sknjct-003 To Non-Invasively Treat Basal Cell Carcinoma (Bcc) Of The Skin

Medicus Pharma Wins UK Regulatory Approval for Phase 2 Basal Cell Carcinoma Trial

Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (Cnpv) for Sknjct-003 to Non-Invasively Treat Basal Cell Carcinoma (Bcc) of the Skin

THOMSON REUTERS

Medicus Pharma Reports Q3 Loss Amid Strategic Growth

Medicus Pharma Q3 EPS $(1.12) Misses $(0.29) Estimate

Medicus Pharma Ltd. reports Q3 cash and cash equivalents of $8.7 million and operating expenses of $15.4 million

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma receives full UK regulatory approvals to expand Phase 2 study

Medicus Pharma Ltd’s Strategic Collaboration and Promising Phase 2 Results Justify Buy Rating

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Partners with Gorlin Syndrome Alliance to Advance SKINJECT Access

Medicus Pharma Ltd - and Gsa to Pursue Expanded Access Ind Program With FDA

THOMSON REUTERS

Medicus Pharma Ltd. Announces Collaboration With the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject™ in Patients With Gorlin Syndrome

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MDCX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":1.89,"timestamp":1765573200000,"preClose":1.95,"halted":0,"volume":259464,"hourTrading":{"tag":"盘后","latestPrice":1.92,"preClose":1.89,"latestTime":"18:23 EST","volume":1211,"amount":2322.765,"timestamp":1765581836100},"delay":0,"floatShares":15486500,"shares":22029100,"eps":-2.310262,"marketStatus":"Market Closed","change":-0.06,"latestTime":"12-12 16:00:00 EST","open":2,"high":2,"low":1.87,"amount":501069.2745048,"amplitude":0.066667,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.310262,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":1.95,"preHourTrading":{"tag":"盘前","latestPrice":2,"preClose":1.95,"latestTime":"08:53 EST","volume":2926,"amount":5852,"timestamp":1765547619604},"postHourTrading":{"tag":"盘后","latestPrice":1.92,"preClose":1.89,"latestTime":"18:23 EST","volume":1211,"amount":2322.765,"timestamp":1765581836100},"volumeRatio":0.7343972013443907},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":15486500,"roa":"-170.69%","roe":"-2660.81%","lyrEps":-1.159715,"volumeRatio":0.7343972013443907,"shares":22029100,"dividePrice":0,"high":2,"amplitude":0.066667,"preClose":1.95,"low":1.87,"week52Low":1.675,"pbRate":"-45.75","week52High":8.94,"institutionHeld":0,"latestPrice":1.89,"eps":-2.310262,"divideRate":0,"volume":259464,"delay":0,"ttmEps":-2.310262,"open":2,"prevYearClose":2.43,"prevWeekClose":2.05,"prevMonthClose":2.2,"prevQuarterClose":2.315,"fiveDayClose":2.05,"twentyDayClose":2.26,"sixtyDayClose":2.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"Post Market","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744606800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2025-12-12","current":-0.818089,"percent":0.961039,"low":-3.23298,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"high":-1.066002,"avg":-2.377249,"sd":0.661376,"marketCap":42956830},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830}],"updateTime":1765641935874},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589817322","title":"Medicus Pharma Raises $5.1 Million Through Warrant Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2589817322","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589817322?lang=en_us&edition=fundamental","pubTime":"2025-12-06 04:21","pubTimestamp":1764966094,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the immediate exercise of all outstanding Series A and Series B Warrants, originally issued on July 14, 2025, following a warrant inducement agreement. The exercise price of the warrants was amended to $1.92 per share, resulting in the purchase of 2,680,000 common shares and expected gross proceeds of approximately $5.1 million before fees and expenses. The transaction is expected to close on or about December 5, 2025, subject to customary conditions. Maxim Group LLC is serving as the exclusive financial advisor for the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via ACCESS Newswire  on December 05, 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL6DXcyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2588278597","title":"Medicus Pharma Names Carolyn Bonner President and CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2588278597","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588278597?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592259,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has appointed Carolyn Bonner as Chief Financial Officer in addition to her role as President. Bonner has been serving as Acting CFO since September 2025, following the medical leave and subsequent resignation of former CFO Jim Quinlan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL4xwFFH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","BK4585","IE00B64PRP62.GBP","MDCX","NDAQ","BK4588","LU2210149790.SGD","LU2210150020.SGD","BK4112"],"gpt_icon":0},{"id":"2588012722","title":"Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President","url":"https://stock-news.laohu8.com/highlight/detail?id=2588012722","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588012722?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUABDFYQZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2585946297","title":"Medicus Pharma Completes Acquisition of UK-Based Biotech Antev","url":"https://stock-news.laohu8.com/highlight/detail?id=2585946297","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585946297?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989218,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has completed the acquisition of Antev, a UK-based late clinical stage biotech company. Antev is developing Teverelix, a next generation GnRH antagonist intended as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and for those experiencing first acute urinary retention relapse episodes due to enlarged prostate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6jZT61:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4139","MDCX","NDAQ","BK4588"],"gpt_icon":0},{"id":"2585462982","title":"Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462982","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462982?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989200,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Nov.  24, 2025  (GLOBE NEWSWIRE) -- November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer– espe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/24/3193414/0/en/Medicus-Pharma-Ltd-Explore-Novel-Treatment-Innovations-that-may-Revolutionize-Treatments-for-Prostate-and-Skin-Cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443382.USD","LU1066051225.USD","LU1935043536.SGD","MDCX","LU1935043023.USD","LU0786609619.USD","LU0157215616.USD","LU1496350171.SGD","LU0077335932.USD","LU1935042488.USD","LU2083900584.USD","LU1674673428.USD","LU2237443549.SGD","LU1066051498.USD","LU1366333091.USD","LU0053666078.USD","LU1366192091.USD","APC","LU1935042215.USD","LU1066051811.HKD","LU2237443978.SGD","BK4139","LU1066053197.SGD","BK4104","LU1778281490.HKD","BK4567","LU0882574139.USD","MNA","BCC","LU0314104364.USD","LU1718418525.SGD","LU1674673691.USD","LU0170899867.USD","LU2417539215.USD","LU1935042991.SGD","LU2420271590.USD","LU2236285917.USD","LU2456880835.USD","LU0149725797.USD","LU2237443622.USD"],"gpt_icon":0},{"id":"2584575349","title":"Optimistic Buy Rating for Medicus Pharma Ltd Driven by Promising SkinJect Developments and Strategic Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2584575349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584575349?lang=en_us&edition=fundamental","pubTime":"2025-11-19 01:55","pubTimestamp":1763488529,"startTime":"0","endTime":"0","summary":"Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Medicus Pharma Ltd. The associated price target remains the same with $20...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-medicus-pharma-ltd-driven-by-promising-skinject-developments-and-strategic-initiatives-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-medicus-pharma-ltd-driven-by-promising-skinject-developments-and-strategic-initiatives-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX"],"gpt_icon":0},{"id":"2584762607","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584762607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584762607?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:39","pubTimestamp":1763386740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 08:39 ET (13:39 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2584623331","title":"BRIEF-Medicus Pharma Announces Filing Of FDA Commissioner’s National Priority Voucher Application (Cnpv) For Sknjct-003 To Non-Invasively Treat Basal Cell Carcinoma (Bcc) Of The Skin","url":"https://stock-news.laohu8.com/highlight/detail?id=2584623331","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584623331?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:35","pubTimestamp":1763382905,"startTime":"0","endTime":"0","summary":"BRIEF-Medicus Pharma Announces Filing Of FDA Commissioner’s National Priority Voucher Application (Cnpv) For Sknjct-003 To Non-Invasively Treat Basal Cell Carcinoma (Bcc) Of The SkinNov 17 (Reuters) -","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT16W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2584623364","title":"Medicus Pharma Wins UK Regulatory Approval for Phase 2 Basal Cell Carcinoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2584623364","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584623364?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:34","pubTimestamp":1763382881,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced it received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study  evaluating the Doxorubicin Microneedle Array  for the non-invasive treatment of basal cell carcinoma  of the skin. The approvals were granted by the Medicines and Healthcare products Regulatory Agency , the Health Research Authority , and the Wales Research Ethics Committee , following a comprehensive review process. Additionally, Medicus Pharma has submitted an FDA Commissioner's National Priority Voucher  application in the United States for the same program, aiming to align with national priorities in cancer care access, affordability, and rare-disease needs. No other organizations are noted as recipients of these approvals or submissions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL1JXYWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4585","BK4139","LU2095319765.USD","MDCX","BK4588","LU2210149790.SGD","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2584628007","title":"Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (Cnpv) for Sknjct-003 to Non-Invasively Treat Basal Cell Carcinoma (Bcc) of the Skin","url":"https://stock-news.laohu8.com/highlight/detail?id=2584628007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584628007?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:30","pubTimestamp":1763382637,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT16W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2583680609","title":"Medicus Pharma Reports Q3 Loss Amid Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680609","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680609?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:54","pubTimestamp":1763160845,"startTime":"0","endTime":"0","summary":"An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. On November 14, 2025, Medicus Pharma Ltd. announced its financial and operating res...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-reports-q3-loss-amid-strategic-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-reports-q3-loss-amid-strategic-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2583768274","title":"Medicus Pharma Q3 EPS $(1.12) Misses $(0.29) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583768274","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583768274?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:01","pubTimestamp":1763157715,"startTime":"0","endTime":"0","summary":"Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.29) by 286.21 percent. This is a 366.67 percent decrease over losses of $(0.24) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48882518/medicus-pharma-q3-eps-1-12-misses-0-29-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Medicus Pharma Q3 EPS $(1.12) Misses $(0.29) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2583827936","title":"Medicus Pharma Ltd. reports Q3 cash and cash equivalents of $8.7 million and operating expenses of $15.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583827936","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583827936?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:00","pubTimestamp":1763157624,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. reported cash and cash equivalents of $8.7 million at the end of the third quarter of 2025, up from $5.3 million at the same period in 2024. Total operating expenses for the third quarter were $15.4 million, compared to $2.3 million in the previous year's third quarter. The company raised $10.4 million through financing transactions and warrant exercises during the quarter. Key business developments included progress in the clinical development programs for the doxorubicin-containing microneedle array  and Teverelix, as well as the completion of the acquisition of Antev and ongoing global expansion of the SkinJect clinical program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the orig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL995NFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2583598730","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598730","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598730?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:20","pubTimestamp":1763040000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 08:20 ET (13:20 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2583560766","title":"Medicus Pharma receives full UK regulatory approvals to expand Phase 2 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560766","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560766?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:55","pubTimestamp":1763038514,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study evaluat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-receives-full-uk-regulatory-approvals-to-expand-phase-2-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-receives-full-uk-regulatory-approvals-to-expand-phase-2-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2579171929","title":"Medicus Pharma Ltd’s Strategic Collaboration and Promising Phase 2 Results Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2579171929","media":"TIPRANKS","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579171929?lang=en_us&edition=fundamental","pubTime":"2025-10-31 03:55","pubTimestamp":1761854113,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group reiter...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltds-strategic-collaboration-and-promising-phase-2-results-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltds-strategic-collaboration-and-promising-phase-2-results-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX"],"gpt_icon":0},{"id":"2579906262","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2579906262","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579906262?lang=en_us&edition=fundamental","pubTime":"2025-10-29 20:56","pubTimestamp":1761742560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2025 08:56 ET (12:56 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2579770889","title":"Medicus Pharma Partners with Gorlin Syndrome Alliance to Advance SKINJECT Access","url":"https://stock-news.laohu8.com/highlight/detail?id=2579770889","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579770889?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:30","pubTimestamp":1761737418,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced a strategic collaboration with the Gorlin Syndrome Alliance  to pursue compassionate use access for SKINJECT, its investigational doxorubicin-containing microneedle therapy, in patients with Gorlin Syndrome. This partnership aims to secure approval under the FDA's Expanded Access IND Program, allowing patients with multiple, recurrent, or inoperable basal cell carcinomas to receive supervised treatment with SKINJECT. The initiative will also facilitate the collection of real-world safety and tolerability data and integrate patient community insights into the ongoing development of the therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL3m1hYw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4588","MDCX","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD"],"gpt_icon":0},{"id":"2579977499","title":"Medicus Pharma Ltd - and Gsa to Pursue Expanded Access Ind Program With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2579977499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579977499?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:30","pubTimestamp":1761737401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA5C20WT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2579493977","title":"Medicus Pharma Ltd. Announces Collaboration With the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject™ in Patients With Gorlin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2579493977","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579493977?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:30","pubTimestamp":1761737401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA5C20WT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}]}}